UB Paderborn / Katalog / Suche / in CDI

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

Archives of pathology & laboratory medicine (1976), 2018-11, Vol.142 (11), p.1364-1382

2018

Link zum Volltext

Verfügbarkeit prüfen

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

Archives of pathology & laboratory medicine (1976), 2014-02, Vol.138 (2), p.241-256

2014

Link zum Volltext

Verfügbarkeit prüfen

The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells

Cancer research (Chicago, Ill.), 2006-06, Vol.66 (12), p.6412-6420

2006

Link zum Volltext

Verfügbarkeit prüfen

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

Journal of clinical oncology, 2018-07, Vol.36 (20), p.2105-2122

2018

Link zum Volltext

Verfügbarkeit prüfen

Addressing overtreatment of screen detected DCIS; the LORIS trial

European journal of cancer (1990), 2015-11, Vol.51 (16), p.2296-2303

2015

Link zum Volltext

Verfügbarkeit prüfen

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

Journal of clinical oncology, 2013-11, Vol.31 (31), p.3997-4013

2013

Link zum Volltext

Verfügbarkeit prüfen

GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer

Clinical cancer research, 2020-09, Vol.26 (18), p.4901-4910

2020

Link zum Volltext

Verfügbarkeit prüfen

Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations

Journal of clinical oncology, 2009-03, Vol.27 (8), p.1323-1333

2009

Link zum Volltext

Verfügbarkeit prüfen

HER2 testing: Current status and future directions

Cancer treatment reviews, 2014-03, Vol.40 (2), p.276-284

2014

Link zum Volltext

Verfügbarkeit prüfen

Benchmarking to the Gold Standard: Hyaluronan‐Oxime Hydrogels Recapitulate Xenograft Models with In Vitro Breast Cancer Spheroid Culture

Advanced materials (Weinheim), 2019-09, Vol.31 (36), p.e1901166-n/a

2019

Link zum Volltext

Verfügbarkeit prüfen

Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program

European journal of cancer (1990), 2017-09, Vol.82, p.219-227

2017

Link zum Volltext

Verfügbarkeit prüfen

Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations

Journal of clinical oncology, 2010-04, Vol.28 (12), p.2114-2122

2010

Link zum Volltext

Verfügbarkeit prüfen

Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study

Journal of clinical oncology, 2014-09, Vol.32 (27), p.2951-2958

2014

Link zum Volltext

Verfügbarkeit prüfen

Ductal carcinoma in situ of the breast: can biomarkers improve current management?

Clinical chemistry (Baltimore, Md.), 2014-01, Vol.60 (1), p.60-67

2014

Link zum Volltext

Verfügbarkeit prüfen

HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2

European journal of cancer (1990), 2017-07, Vol.79, p.129-138

2017

Link zum Volltext

Verfügbarkeit prüfen

GSK3β and cyclin D1 expression predicts outcome in early breast cancer patients

Breast cancer research and treatment, 2012-11, Vol.136 (1), p.161-168

2012

Link zum Volltext

Verfügbarkeit prüfen

Association of galectin-3 expression with melanoma progression and prognosis

European journal of cancer (1990), 2012-04, Vol.48 (6), p.865-874

2012

Link zum Volltext

Verfügbarkeit prüfen

Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor–positive early breast cancer patients

Breast cancer research and treatment, 2012-05, Vol.133 (1), p.49-59

2012

Link zum Volltext

Verfügbarkeit prüfen

The androgen receptor and signal‐transduction pathways in hormone‐refractory prostate cancer. Part 1: modifications to the androgen receptor

BJU international, 2005-06, Vol.95 (9), p.1320-1326

2005

Link zum Volltext

Verfügbarkeit prüfen

Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy Trial

Journal of clinical oncology, 2008-11, Vol.26 (31), p.5027-5035

2008

Link zum Volltext

Verfügbarkeit prüfen

Mammostrat As an Immunohistochemical Multigene Assay for Prediction of Early Relapse Risk in the Tamoxifen Versus Exemestane Adjuvant Multicenter Trial Pathology Study

Journal of clinical oncology, 2012-12, Vol.30 (36), p.4477-4484

2012

Link zum Volltext

Verfügbarkeit prüfen

Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial

Archives of pathology & laboratory medicine (1976), 2016-01, Vol.140 (1), p.66-74

2016

Link zum Volltext

Verfügbarkeit prüfen

The androgen receptor and signal‐transduction pathways in hormone‐refractory prostate cancer. Part 2: androgen‐receptor cofactors and bypass pathways

BJU international, 2005-06, Vol.95 (9), p.1327-1335

2005

Link zum Volltext

Verfügbarkeit prüfen

Ras/Raf-1/MAPK Pathway Mediates Response to Tamoxifen but not Chemotherapy in Breast Cancer Patients

Clinical cancer research, 2009-02, Vol.15 (4), p.1487-1495

2009

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

Addressing overtreatment of screen detected DCIS; the LORIS trial

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer

Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations

HER2 testing: Current status and future directions

Benchmarking to the Gold Standard: Hyaluronan‐Oxime Hydrogels Recapitulate Xenograft Models with In Vitro Breast Cancer Spheroid Culture

Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program

Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations

Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study

Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial

Ductal carcinoma in situ of the breast: can biomarkers improve current management?

HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2

GSK3β and cyclin D1 expression predicts outcome in early breast cancer patients

Association of galectin-3 expression with melanoma progression and prognosis

Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor–positive early breast cancer patients

The androgen receptor and signal‐transduction pathways in hormone‐refractory prostate cancer. Part 1: modifications to the androgen receptor

Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy Trial

Mammostrat As an Immunohistochemical Multigene Assay for Prediction of Early Relapse Risk in the Tamoxifen Versus Exemestane Adjuvant Multicenter Trial Pathology Study

Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial

The androgen receptor and signal‐transduction pathways in hormone‐refractory prostate cancer. Part 2: androgen‐receptor cofactors and bypass pathways

Ras/Raf-1/MAPK Pathway Mediates Response to Tamoxifen but not Chemotherapy in Breast Cancer Patients

Suchergebnisse filtern